Halozyme (NASDAQ: HALO) CFO reports PSU and RSU vesting, tax shares

Rhea-AI Filing Summary

Halozyme Therapeutics SVP & CFO Nicole LaBrosse reported equity award vesting and related tax-withholding transactions. On February 23, 6,688 Performance Stock Units were exercised into 6,688 shares of common stock, and 3,608 shares were withheld at $70.64 per share to cover taxes. On February 20, 5,332 Restricted Stock Units vested into 5,332 common shares, with 2,876 shares withheld at $70.98 per share for tax obligations. After these transactions, she directly held 38,494 shares of common stock, 36,357 Performance Stock Units, and 15,995 Restricted Stock Units.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LaBrosse Nicole

(Last) (First) (Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/20/2026		M		5,332	A	$0	38,290	D
Common Stock	02/20/2026		F		2,876(1)	D	$70.98	35,414	D
Common Stock	02/23/2026		M		6,688	A	$0	42,102	D
Common Stock	02/23/2026		F		3,608(2)	D	$70.64	38,494	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	02/20/2026		M			5,332	(3)	(3)	Common Stock	5,332	$0	15,995	D
Performance Stock Units	$0	02/23/2026		M			6,688	(3)	(3)	Common Stock	6,688	$0	36,357	D

Explanation of Responses:

1. The reported disposition of 2,876 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.

2. The reported disposition of 3,608 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.

3. This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.

Remarks:

	/s/ James R. Oehler, Attorney-in-Fact	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Halozyme (HALO) CFO Nicole LaBrosse report in this Form 4?

Halozyme CFO Nicole LaBrosse reported the vesting and settlement of Performance Stock Units and Restricted Stock Units into common stock, along with share dispositions used to cover tax withholding obligations related to those equity awards, rather than open-market purchases or sales of Halozyme shares.

How many Halozyme shares did Nicole LaBrosse receive from equity award vesting?

Nicole LaBrosse received 6,688 Halozyme common shares from Performance Stock Units on February 23 and 5,332 common shares from Restricted Stock Units on February 20. These transactions reflect the conversion of previously granted equity awards into issued shares of common stock.

Were any of Nicole LaBrosse’s Halozyme share dispositions open-market sales?

The reported dispositions were not open-market sales. A total of 2,876 shares on February 20 and 3,608 shares on February 23 were withheld by Halozyme as payment for tax withholding obligations tied to the vesting and settlement of LaBrosse’s stock unit awards.

What were Nicole LaBrosse’s Halozyme holdings after these Form 4 transactions?

After the reported transactions, Nicole LaBrosse directly held 38,494 shares of Halozyme common stock, 36,357 Performance Stock Units, and 15,995 Restricted Stock Units. These figures reflect her direct ownership positions following the vesting, settlement, and tax-withholding share dispositions.

On what dates did Nicole LaBrosse’s Halozyme equity awards vest?

LaBrosse’s Halozyme equity awards vested on two dates: Restricted Stock Units vested and settled into 5,332 common shares on February 20, and Performance Stock Units converted into 6,688 common shares on February 23, with both events reported in this Form 4 filing.

What prices were used for Halozyme shares withheld for Nicole LaBrosse’s taxes?

Halozyme withheld 2,876 shares at $70.98 per share on February 20 and 3,608 shares at $70.64 per share on February 23. These withheld shares satisfied Nicole LaBrosse’s tax withholding obligations connected to the vesting of her stock unit awards.